Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion type Assertion NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_head.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion description "[Expression and functional activity of P-glycoprotein (P-gp) were measured in 182 acute myelogenous leukemia (AML) patients: 136 patients were treated with the AML-6 protocol (EORTC), containing daunorubicin, vincristine, and conventional-dose cytarabine (ara-C), and 21 patients received idarubicin, vepeside, and conventional-dose ara-C (ICE-AML-10 protocol/EORTC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_provenance.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion evidence source_evidence_literature NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_provenance.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion SIO_000772 9322679 NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_provenance.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion wasDerivedFrom befree-20140225 NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_provenance.
- NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_assertion wasGeneratedBy ECO_0000203 NP861434.RADvjJILlPkH_etHPYsN4IRx-MuKcjRfRdv3IipE1xnbQ130_provenance.